Alzheimer's regulatory and reimbursement landscape, as of Q2 2026
Two anti-amyloid antibodies have traditional FDA approval; CMS coverage operates under a coverage-with-evidence-development framework; international approvals diverge.
Regulatory clarity has improved; reimbursement clarity is still evolving; international access still varies meaningfully across major markets.
A factual snapshot of the regulatory and reimbursement environment for disease-modifying Alzheimer's therapies in mid-2026.
United States
FDA. Lecanemab and donanemab have traditional FDA approval for early symptomatic Alzheimer's disease with confirmed amyloid pathology. Aducanumab was withdrawn voluntarily in 2024. Anti-amyloid accelerated-approval submissions have faced sharper advisory committee scrutiny in the post-aducanumab period; biomarker-only approvals are no longer the default expectation.
CMS. Coverage operates under the coverage-with-evidence-development framework, requiring registry participation for anti-amyloid antibody prescribing. The framework's effect on rollout shape is significant — discussed in our Signal on the CED impact.
Diagnostics. Several plasma biomarker assays have FDA in-vitro diagnostic clearance. Amyloid PET is Medicare-covered for diagnostic clarification under defined indications.
European Union
The European Medicines Agency has taken a more cautious approach to the anti-amyloid antibody class than the FDA. Authorization decisions and label scope have differed from the US, with national-level reimbursement decisions adding further variation. Patient access is materially more constrained than in the US.
United Kingdom
Anti-amyloid antibodies have received MHRA authorization but have faced cost-effectiveness challenges at NICE. NHS routine commissioning has been limited or delayed in major indications; private-pay channels exist but address a narrow population.
Japan
Lecanemab received early approval in Japan and is reimbursed under specific conditions, with notable adoption in academic centers. The Japanese rollout has been a useful real-world reference for several operational questions in the US.
Other major markets
Approvals and reimbursement decisions are at different stages across other major markets, including Canada, Australia, China, and several middle-income geographies. The global access map is markedly more uneven than the FDA-approval timeline alone would suggest.
What this snapshot does not capture
National-level guidelines and reimbursement decisions can lag central authorizations meaningfully. Cost-effectiveness assessments are ongoing in several jurisdictions and have produced divergent conclusions even on similar evidence bases. Real-world access — as opposed to formal authorization — varies considerably within markets as well as across them.
Key sources
- FDA approval letters — lecanemab (Leqembi) and donanemab (Kisunla)
- CMS National Coverage Determination 200.3 — anti-amyloid coverage
- EMA opinions and authorization decisions on anti-amyloid antibodies
- NICE technology appraisals on anti-amyloid Alzheimer's therapy